PharmiGene, Inc (PGI), specializing in pharmacogenomic testing, holds patents across Taiwan, China, the US, Europe, and other regions. Our mission is to assist individuals in receiving the most suitable treatments while minimizing adverse drug reactions.
In 2024, to expand PGI into international markets and broaden our business scope, we established a subsidiary in Vietnam. This initiative focuses on genetic testing, accompanied by intelligent medical devices, novel testing instruments, and bespoke health products. These offerings provide comprehensive solutions tailored to both domestic and international market demands.
Simultaneously, PGI has expedited our Contract Development and Manufacturing Organization (CDMO) services. The new facilities, compliant with ISO 13485 and QMS certifications, offer CDMO services for In Vitro Diagnostic (IVD) production. Supporting various technical platforms and flexible production volumes ensures timely delivery to meet client needs. Additionally, we are consolidating and planning to expand our agency business by offering products from 10x Genomics, S2 Genomics, Immudex, Abiosciences, and VarSome, thus broadening our business scope.
Furthermore, PGI is fostering strategic collaborations with medical centers, leveraging our testing technology to develop new business models. From product performance testing to clinical validation, PGI provides end-to-end services, creating a mutually beneficial scenario for our clients and clinical partners. Upholding our commitment to professional specialization, we strive to cultivate mutual success with our clients.